8-K: Vivani Medical to Present at Emerging Growth Conference

Vivani Medical, a biopharmaceutical company, will present at the Emerging Growth Conference on September 25, 2024, to discuss its long-acting drug implant technology.

Summary

• Vivani Medical announced it will present at the Emerging Growth Conference on September 25, 2024.
• The presentation will be an interactive online event where the company's President and CEO, Adam Mendelsohn, Ph.D., will provide a company overview.
• Vivani is developing miniaturized, ultra long-acting drug implants using its NanoPortal platform.
• Their lead program, NPM-115, is a six-month subdermal GLP-1 (exenatide) implant for chronic weight management.
• They are also developing NPM-139, a semaglutide implant for chronic weight management, with the potential for once-yearly administration.
• NPM-119 is a six-month subdermal exenatide implant for Type 2 Diabetes.
• Vivani's implants aim to improve medication adherence, addressing the issue of non-adherence which affects approximately 50% of patients and contributes to significant healthcare costs and preventable deaths.
• Vivani's subsidiary, Cortigent, is developing neurostimulation systems, including the Orion device for artificial vision and a system for stroke recovery.
• Vivani is assessing strategic options for Cortigent's technology.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the company's upcoming presentation and innovative technology. However, it also acknowledges the risks associated with drug development and the company's financial history, preventing a higher score.

Positives

• Vivani's long-acting implants aim to improve medication adherence, a significant issue in healthcare.
• The company has a pipeline of products targeting large markets such as chronic weight management and Type 2 Diabetes.
• The semaglutide implant (NPM-139) has the potential for once-yearly administration, offering a significant convenience advantage.
• Cortigent's neurostimulation technology has the potential to address critical unmet medical needs.

Negatives

• The document highlights the risks associated with the development and commercialization of Vivani's products.
• The company has a history of losses and may need to access additional capital to fund its business.
• There are risks related to the initiation, enrollment, and conduct of planned clinical trials.

Risks

• There are risks related to the development and commercialization of Vivani's products, including NPM-115 and NPM-119.
• Delays and changes in the development of Vivani's products could occur due to applicable laws, regulations, and guidelines.
• There are potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities.
• The company faces risks related to the initiation, enrollment, and conduct of planned clinical trials.
• Vivani has a history of losses and may need to access additional capital.
• Market conditions and the ability of Cortigent to complete its initial public offering are also risks.

Future Outlook

The company is focused on the development of its drug implant pipeline and is assessing strategic options for its subsidiary, Cortigent. The company plans to continue clinical trials and seek regulatory approvals for its products.

Management Comments

• Adam Mendelsohn, Ph.D., President and CEO, will deliver a company overview at the Emerging Growth Conference.
• The company is confident that its differentiated portfolio of miniature long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers.

Industry Context

The announcement highlights Vivani's participation in the Emerging Growth Conference, indicating an effort to increase visibility within the investment community. The company's focus on long-acting drug implants aligns with the industry trend towards improving medication adherence and patient convenience. The GLP-1 market is competitive, with over 50 new molecular entities under clinical stage development, but Vivani believes its technology is differentiated.

Comparison to Industry Standards

• Vivani's approach to drug delivery via long-acting implants is similar to companies like Intarcia Therapeutics, which was developing a long-acting implantable device for Type 2 Diabetes, though Intarcia faced significant challenges.
• The focus on GLP-1 agonists for weight management and diabetes places Vivani in competition with companies like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro), which have established injectable products in this space.
• Vivani's technology aims to differentiate itself through the use of miniaturized implants and extended release profiles, potentially offering advantages over daily or weekly injections.
• The development of neurostimulation devices by Cortigent is comparable to companies like Second Sight Medical Products, which developed the Argus II retinal prosthesis, though Cortigent is also exploring applications in stroke recovery.

Stakeholder Impact

• Shareholders will have the opportunity to learn more about the company's strategy and technology at the Emerging Growth Conference.
• Patients could benefit from improved medication adherence and more convenient treatment options.
• The company's success could lead to job creation and economic growth.

Next Steps

• Vivani will present at the Emerging Growth Conference on September 25, 2024.
• The company will continue to develop its drug implant pipeline.
• Vivani will assess strategic options for advancing Cortigent's technology.

Key Dates

Keywords

drug implants, biopharmaceutical, GLP-1, exenatide, semaglutide, weight management, Type 2 Diabetes, medication adherence, neurostimulation, clinical trials, NanoPortal, Cortigent